Market Overview

Jefferies Reiterates Buy Rating, $36 PT on Incyte Corporation Despite PML Case

Share:
Related INCY
After-Hours Recap: Bed Bath & Beyond, Apollo, Valeant, eBay & More
Mid-Day Market Update: Crude Oil Down 2.8%; KB Home Shares Surge Following Strong Results

In a report published Monday, Jefferies analyst Thomas Wei reiterated a Buy rating and $36.00 price target on Incyte Corporation (NASDAQ: INCY).

In the report, Wei noted, “INCY today disclosed a 75-year old male patient developed PML, a rare brain infection, while taking Jakafi. We still believe that the overall risk-benefit profile of Jakafi is favorable and note that the causal relationship between Jakafi and the PML case is unclear with spontaneous reports of PML in the myelofibrosis literature, and there has been a favorable trend on overall survival seen in the Phase 3 trials.”

Incyte Corporation closed on Friday at $24.84.

Latest Ratings for INCY

DateFirmActionFromTo
Apr 2016BMO CapitalInitiates Coverage onOutperform
Mar 2016Morgan StanleyInitiates Coverage onOverweight
Feb 2016Leerink SwannMaintainsOutperform

View More Analyst Ratings for INCY
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Reiteration Analyst Ratings

 

Related Articles (INCY)

View Comments and Join the Discussion!